The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...

Mounjaro will be rolled out gradually as officials said a "difficult decision" had to be made in order to "protect other ...

We’ve had to make this difficult decision in order to protect vital NHS services and also to test ways of delivering this new ...

However, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, warned that weight loss jabs “are not a ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

However the NHS spending watchdog has announced Mounjaro will only be given to 220,000 people in England during the first three years - despite 3.4 million people being eligible for it. Trials have ...

Jim Gaffigan revealed he lost 50 pounds via a weight loss drug after struggling for years with his weight. Photos show the ...

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head ...